This study aims to evaluate, through a multicenter, prospective, double-blind, randomized, placebo-controlled clinical trial, whether immunosuppressive therapy improves target lesion-related cardiovascular outcomes compared to placebo treatment in patients with Rapid rEcurrence of Coronary Unexplained in-stent Restenosis (RECUR).

Inclusion Criteria:

1. Age ≥ 18 years old
2. Able to understand the trial design and sign an informed consent form
3. Patients meeting the RECUR definition
4. Satisfactory results from revascularization within the past two weeks
5. Receiving standard secondary prevention medication for coronary heart disease with treatment targets achieved

Exclusion Criteria:

Pregnant women, individuals known to be allergic to the study drug, those currently participating in other interventional clinical trials, or participants deemed unsuitable for this study based on the investigator's judgment.